ICLR vs. INCY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ICLR and INCY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ICLR | INCY |
|---|---|---|
| Company Name | ICON Public Limited Company | Incyte Corporation |
| Country | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 13.67 billion USD | 16.61 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | May 15, 1998 | November 4, 1993 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ICLR and INCY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ICLR | INCY |
|---|---|---|
| 5-Day Price Return | -1.53% | 0.14% |
| 13-Week Price Return | 38.86% | 31.28% |
| 26-Week Price Return | -6.80% | 19.32% |
| 52-Week Price Return | -45.59% | 32.56% |
| Month-to-Date Return | 3.92% | 13.55% |
| Year-to-Date Return | -16.16% | 23.12% |
| 10-Day Avg. Volume | 1.07M | 1.84M |
| 3-Month Avg. Volume | 1.52M | 1.84M |
| 3-Month Volatility | 58.13% | 36.23% |
| Beta | 1.25 | 0.74 |
Profitability
Return on Equity (TTM)
ICLR
8.28%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
ICLR’s Return on Equity of 8.28% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
INCY
24.09%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 24.09% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
ICLR
9.82%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
ICLR’s Net Profit Margin of 9.82% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
INCY
18.99%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 18.99% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ICLR
12.50%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
ICLR’s Operating Profit Margin of 12.50% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
INCY
25.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 25.80% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ICLR | INCY |
|---|---|---|
| Return on Equity (TTM) | 8.28% | 24.09% |
| Return on Assets (TTM) | 4.71% | 15.81% |
| Net Profit Margin (TTM) | 9.82% | 18.99% |
| Operating Profit Margin (TTM) | 12.50% | 25.80% |
| Gross Profit Margin (TTM) | 28.65% | 93.41% |
Financial Strength
Current Ratio (MRQ)
ICLR
1.29
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
ICLR’s Current Ratio of 1.29 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
INCY
2.85
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
INCY’s Current Ratio of 2.85 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ICLR
0.36
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
ICLR’s Debt-to-Equity Ratio of 0.36 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
INCY
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ICLR
4.80
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
ICLR’s Interest Coverage Ratio of 4.80 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ICLR | INCY |
|---|---|---|
| Current Ratio (MRQ) | 1.29 | 2.85 |
| Quick Ratio (MRQ) | 1.24 | 2.55 |
| Debt-to-Equity Ratio (MRQ) | 0.36 | 0.01 |
| Interest Coverage Ratio (TTM) | 4.80 | 6.86 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ICLR
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
ICLR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ICLR
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
ICLR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ICLR | INCY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ICLR
17.61
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
In the lower quartile for the Life Sciences Tools & Services industry, ICLR’s P/E Ratio of 17.61 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
INCY
19.33
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
INCY’s P/E Ratio of 19.33 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ICLR
1.73
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
In the lower quartile for the Life Sciences Tools & Services industry, ICLR’s P/S Ratio of 1.73 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
INCY
3.67
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 3.67 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
ICLR
1.21
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
ICLR’s P/B Ratio of 1.21 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
INCY
3.16
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
INCY’s P/B Ratio of 3.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ICLR | INCY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 17.61 | 19.33 |
| Price-to-Sales Ratio (TTM) | 1.73 | 3.67 |
| Price-to-Book Ratio (MRQ) | 1.21 | 3.16 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.14 | 17.57 |